Pharming Group N.V.
No enriched coverage for $PHAR in the last 7 days.
No SEC Form 4 filings for $PHAR in the last 30 days.
See all $PHAR insider activity →The FDA approved Pharming's Joenja for treating children aged 4-11 with APDS, a rare immunodeficiency. The Dutch biopharma firm (PHARM) expects the new pediatric doses to be available in the US in October. This marks the first FDA-approved treatment for this age group with APDS.
Pharming Group (PHAR) said Joenja (leniolisib) has started commercial sales in Japan for APDS patients aged 4 and older, after inclusion on Japan’s NHI price list. The drug is an oral PI3K delta inhibitor approved based on a Phase III trial and supported by long-term extension data. OrphanPacific is the local partner.
Pharming Group N.V. (PHAR) furnished an SEC Form 6-K — earnings release. Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated July 30, 2026. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja mom
Recent PHAR coverage spans financial news, earnings and regulation.
The FDA approved Pharming's Joenja for treating children aged 4-11 with APDS, a rare immunodeficiency. The Dutch biopharma firm (PHARM) expects the new pediatric doses to be available in the US in October. This marks the first FDA-approved treatment for this age group with APDS.
Japan launch and NHI listing should improve reimbursement-driven demand visibility for Joenja, supporting near-term sentiment and longer-term sales ramp expectations.
Earnings miss and guidance cut may pressure the stock; however, Joenja growth and pipeline could support upside.
Guidance reset increases downside risk to 2026 revenue and profitability, with Ruconest weakness the stated driver.
Guidance cut plus improving operating expense outlook, alongside strong Joenja growth and planned Q4 2026 leniolisib data, sets up a near-term sentiment swing.
AlphAI scores every news story that mentions PHAR with an AI model for sentiment and relevance, and aggregates insider trades from Pharming Group N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA approved Pharming's Joenja for treating children aged 4-11 with APDS, a rare immunodeficiency. The Dutch biopharma firm (PHARM) expects the new pediatric doses to be available in the US in October. This marks the first FDA-approved treatment for this age group with APDS.
1 min readPharming Group (PHAR) said Joenja (leniolisib) has started commercial sales in Japan for APDS patients aged 4 and older, after inclusion on Japan’s NHI price list. The drug is an oral PI3K delta inhibitor approved based on a Phase III trial and supported by long-term extension data. OrphanPacific is the local partner.
3 min readPharming Group N.V. (PHAR) furnished an SEC Form 6-K — earnings release. Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated July 30, 2026. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja mom
2 min readPharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.
4 min readPharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.
7 min readEuropean stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.
4 min readPharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.
4 min readPharming Group said its CEO, Fabrice Chouraqui, will take part in a fireside chat Q&A at the 2026 Jefferies Global Healthcare Conference in New York on June 4 at 11:05am EDT/17:05 CEST. The company will provide a live webcast and replay on its website. The event runs June 3-4, 2026.
1 min readPharming Group said shareholders approved all proposals at its May 28, 2026 AGM. KPMG Accountants N.V. was appointed independent external auditor for 2026–2028. The meeting also approved changes to the Board remuneration policy for non-executive directors and renewed authorizations to issue and repurchase shares, according to the company.
2 min readPharming Group reported its first quarter 2026 financial results, with total revenues decreasing by 8% to US$72.4 million compared to Q1 2025. While RUCONEST® revenue declined due to anticipated inventory drawdowns and market exits, Joenja® revenue grew by 34% to US$14.1 million, driven by strong patient uptake. The company reaffirmed its 2026 total revenue guidance and announced progress on Joenja®'s pediatric label expansion in the U.S. and launches in Japan and Europe.
3 min read
